GlassScriptPhysician profile
Udit Chaudhuri
NPI 1083640569
$8,488.89
in general payments reported to CMS, 2019-2025
47 companies · $46.30 in 2025
The $46.30 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,652 · 2020: $665 · 2021: $1,535 · 2022: $1,608 · 2023: $1,490 · 2024: $1,492 · 2025: $46.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,028.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,042.89 | 2019-2024 | Repatha, Otezla, Evenity |
| Abbvie INC. | $964.56 | 2019-2024 | Vraylar, Ubrelvy, Viberzi |
| Pfizer INC. | $739.09 | 2019-2024 | |
| Novo Nordisk INC | $704.54 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $579.50 | 2019-2025 | |
| Abbott Laboratories | $537.07 | 2022-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $357.52 | 2019-2024 | Airsupra, Farxiga |
| Astellas Pharma US INC | $343.88 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $280.77 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.40 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $217.43 | 2019-2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $215.10 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Amarin Pharma, INC. | $213.00 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $202.80 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $182.53 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Udit Chaudhuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.